4//SEC Filing
Segal Lloyd Mitchell 4
Accession 0001415889-24-009629
CIK 0001808158other
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 9:31 PM ET
Size
9.1 KB
Accession
0001415889-24-009629
Insider Transaction Report
Form 4
Segal Lloyd Mitchell
DirectorPRESIDENT AND CEO
Transactions
- Sale
Common Shares
2024-03-28$4.62/sh−2,650$12,243→ 110,049 total(indirect: See footnote) - Sale
Common Shares
2024-04-01$4.63/sh−2,491$11,533→ 107,558 total(indirect: See footnote)
Holdings
- 102,678
Common Shares
Footnotes (6)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).
- [F3]The change in the total shares prior to the transactions reported herein reflects a change in form of ownership from direct to indirect, which was exempt from reporting pursuant to Rule 16a-13.
- [F4]These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.58 to $4.65 inclusive.
- [F6]Includes 1,217 shares, 967 shares and 2,000 shares acquired on February 15, 2023, August 15, 2023 and February 15, 2024, respectively, under the Issuer's employee stock purchase plan.
Documents
Issuer
Repare Therapeutics Inc.
CIK 0001808158
Entity typeother
Related Parties
1- filerCIK 0001477123
Filing Metadata
- Form type
- 4
- Filed
- Mar 31, 8:00 PM ET
- Accepted
- Apr 1, 9:31 PM ET
- Size
- 9.1 KB